This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Draghi, D. C.
Right arrow Articles by Sahm, D. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Draghi, D. C.
Right arrow Articles by Sahm, D. F.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, July 2008, p. 2383-2388, Vol. 52, No. 7
0066-4804/08/$08.00+0     doi:10.1128/AAC.01641-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Comparative Surveillance Study of Telavancin Activity against Recently Collected Gram-Positive Clinical Isolates from across the United States {triangledown}

Deborah C. Draghi,1 Bret M. Benton,2 Kevin M. Krause,2 Clyde Thornsberry,1 Chris Pillar,1 and Daniel F. Sahm1*

Eurofins Medinet, Inc., Herndon, Virginia,1 Theravance, Inc., South San Francisco, California2

Received 20 December 2007/ Returned for modification 13 February 2008/ Accepted 18 April 2008

Telavancin is an investigational, rapidly bactericidal lipoglycopeptide antibiotic that is being developed to treat serious infections caused by gram-positive bacteria. A baseline prospective surveillance study was conducted to assess telavancin activity, in comparison with other agents, against contemporary clinical isolates collected from 2004 to 2005 from across the United States. Nearly 4,000 isolates were collected, including staphylococci, enterococci, and streptococci (pneumococci, beta-hemolytic, and viridans). Telavancin had potent activity against Staphylococcus aureus and coagulase-negative staphylococci (MIC range, 0.03 to 1.0 µg/ml), independent of resistance to methicillin or to multiple agents. Telavancin activity was particularly potent against all streptococcal groups (MIC90s, 0.03 to 0.12 µg/ml). Telavancin had excellent activity against vancomycin-susceptible enterococci (MIC90, 1 µg/ml) and was active against VanB strains of vancomycin-resistant enterococci (MIC90, 2 µg/ml) but less active against VanA strains (MIC90, 8 to 16 µg/ml). Telavancin also demonstrated activity against vancomycin-intermediate S. aureus and vancomycin-resistant S. aureus strains (MICs, 0.5 µg/ml to 1.0 µg/ml and 1.0 µg/ml to 4.0 µg/ml, respectively). These data may support the efficacy of telavancin for treatment of serious infections with a wide range of gram-positive organisms.

* Corresponding author. Mailing address: Eurofins Medinet, Inc., 13665 Dulles Technology Drive, Suite 200, Herndon, VA 20171-4603. Phone: (703) 480-2536. Fax: (703) 480-2654. E-mail: dan.sahm{at}eurofinsmedinet.com

{triangledown} Published ahead of print on 28 April 2008.

Antimicrobial Agents and Chemotherapy, July 2008, p. 2383-2388, Vol. 52, No. 7
0066-4804/08/$08.00+0     doi:10.1128/AAC.01641-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Arhin, F. F., Draghi, D. C., Pillar, C. M., Parr, T. R. Jr., Moeck, G., Sahm, D. F. (2009). Comparative In Vitro Activity Profile of Oritavancin against Recent Gram-Positive Clinical Isolates. Antimicrob. Agents Chemother. 53: 4762-4771 [Abstract] [Full Text]  
  • Kosowska-Shick, K., Clark, C., Pankuch, G. A., McGhee, P., Dewasse, B., Beachel, L., Appelbaum, P. C. (2009). Activity of Telavancin against Staphylococci and Enterococci Determined by MIC and Resistance Selection Studies. Antimicrob. Agents Chemother. 53: 4217-4224 [Abstract] [Full Text]  
  • Livermore, D. M. (2009). Has the era of untreatable infections arrived?. J Antimicrob Chemother 64: i29-i36 [Abstract] [Full Text]  
  • Lunde, C. S., Hartouni, S. R., Janc, J. W., Mammen, M., Humphrey, P. P., Benton, B. M. (2009). Telavancin Disrupts the Functional Integrity of the Bacterial Membrane through Targeted Interaction with the Cell Wall Precursor Lipid II. Antimicrob. Agents Chemother. 53: 3375-3383 [Abstract] [Full Text]  
  • Leonard, S. N., Vidaillac, C., Rybak, M. J. (2009). Activity of Telavancin against Staphylococcus aureus Strains with Various Vancomycin Susceptibilities in an In Vitro Pharmacokinetic/Pharmacodynamic Model with Simulated Endocardial Vegetations. Antimicrob. Agents Chemother. 53: 2928-2933 [Abstract] [Full Text]  
  • LaPlante, K. L., Mermel, L. A. (2009). In Vitro Activities of Telavancin and Vancomycin against Biofilm-Producing Staphylococcus aureus, S. epidermidis, and Enterococcus faecalis Strains. Antimicrob. Agents Chemother. 53: 3166-3169 [Abstract] [Full Text]  
  • Charneski, L., Patel, P. N, Sym, D. (2009). Telavancin: A Novel Lipoglycopeptide Antibiotic. The Annals of Pharmacotherapy 43: 928-938 [Abstract] [Full Text]  
  • Hegde, S. S., Difuntorum, S., Skinner, R., Trumbull, J., Krause, K. M. (2009). Efficacy of telavancin against glycopeptide-intermediate Staphylococcus aureus in the neutropenic mouse bacteraemia model. J Antimicrob Chemother 63: 763-766 [Abstract] [Full Text]  
  • Pankuch, G. A., Appelbaum, P. C. (2009). Postantibiotic Effects of Telavancin against 16 Gram-Positive Organisms. Antimicrob. Agents Chemother. 53: 1275-1277 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»